A 5‐week trial has found that the combination of the muscarinic receptor agonist xanomeline and the peripheral muscarinic antagonist trospium significantly reduced symptoms of schizophrenia in adults. The xanomeline‐trospium combination was well‐tolerated, with no significant difference from placebo in extrapyramidal symptoms or weight gain.
No takes yet. Share an insight, caveat, or question.
A 2024 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: